Xoma Royalty Corporation · NASDAQ:XOMA
Xoma Royalty — XOMA — Investor Presentation (January 2018)
19 slides from Xoma Royalty's investor presentation, Jan 8, 2018
Slide 1: Corporate Presentation
Corporate Presentation (Nasdaq: XOMA) JANUARY 2018 Exhibit 99.1
Slide 2: Forward-looking Statements
Forward-looking Statements Certain statements in this presentation are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding: future monetization opportunities, active transact
Slide 3: XOMA: A De-risked way to Invest in Biotech
XOMA: A De-risked way to Invest in Biotech Model completely transformed to royalty aggregator with broad asset portfolio and capital resources to seize opportunities
Slide 4: Growth Strategy
Growth Strategy Drive shareholder value by increasing size of portfolio to grow revenue potential and to mitigate risk while maintaining a lean cost structure Build size of portfolio through out-licensing and acquisition of fully-funded assets Public listing provides capital access for company and l
Slide 5: 2017: A Transformational Year at XOMA
2017: A Transformational Year at XOMA 2017 was just the beginning. We have built a foundation, and are now proceeding with a revolutionary plan to create shareholder value. Expanded fully-funded portfolio with 9 new programs Multiple milestone payments received – Novartis & Ology Balance sheet re-ca
Slide 6: Nine New Fully-funded Programs Added in 2017
Nine New Fully-funded Programs Added in 2017 IL-1β / Novartis IL-1β IP Portfolio Gevokizumab Insulin Receptor / Rezolute RZ358 (Formerly X358) AB101 RZ402 RZ406 Phage Display Platform Torch Biosciences Tizona Therapeutics LakePharma PRECLINICAL PHASE 1 PHASE 2 PHASE 3 APPROVAL
Slide 7: Novartis Transaction Underscores our Strategy
Novartis Transaction Underscores our Strategy Build size of portfolio through out-licensing Gevokizumab out-licensed to Novartis IL-1β IP portfolio out-licensed to Novartis Strengthen balance sheet $45M liquidity (cash + debt forgiveness), including $5M equity investment Grow revenue potential Up to
Slide 8: Out-licensed XOMA 358 & Phage Display Platform
Out-licensed XOMA 358 & Phage Display Platform Licensed global development and commercialization rights to Rezolute Up to $240M in potential milestone payments High single-digit to mid-teen royalties Low single-digit royalties on net sales of other products developed by Rezolute Non-exclusive licens
Slide 9: Example Value-Added Partnerships
Example Value-Added Partnerships anti-CD40 Antibody (CFZ533) Multiple ongoing clinical studies Milestones; tiered high-single digit to lower mid-teen royalties TGFβ Antibody Program $480M potential milestones; tiered mid-single to low-double digit royalties Phase 1 Antibody Discovery Proprietary pha
Slide 10: Broad Range of Partnerships
Broad Range of Partnerships Sample of commercial products with XOMA IP held by others
Slide 11: Diversification in Biotech
Diversification in Biotech The binomial distribution model captures the value of a diversified biotech portfolio which classical risk-adjusted, sum-of-the-parts NPV does not. XOMA’s portfolio of licensed assets are diversified across therapeutic areas and development stages. As the size of the portf
Slide 12: Diverse Portfolio Across Therapeutic Areas & Development Stages
Diverse Portfolio Across Therapeutic Areas & Development Stages DEVELOPMENT STAGES THERAPEUTIC AREAS Oncology Inflammation Immunology Infectious Diseases Cardiovascular Other Diabetes Endocrinology Gastroenterology Phase 2
Slide 13: Portfolio Driving Future Milestone and Royalties
Portfolio Driving Future Milestone and Royalties Programs have potential to earn single-digit royalties for 10 years on average Realized Milestone Future Milestone 13
Slide 14: Assets Available for Licensure
Assets Available for Licensure PROGRAM DEVELOPMENT STAGE INDICATION IL-2 Preclinical Immuno-oncology XOMA 213 Phase 2 Various Hyperprolactinemias XMetA Preclinical Diabetes & Rare Diseases Anti-PTH1R Preclinical Hypercalcemia, Endocrine & Oncology
Slide 15: Accelerating Growth by Asset Acquisition
Accelerating Growth by Asset Acquisition We intend to purchase the milestone and royalty obligations that are contractually associated with an underlying drug candidate We DO NOT intend to acquire the underlying asset itself We will differentiate from others in this approach by purchasing assets tha
Slide 16: 2017 Financial Highlights
$13M 2017 Financial Highlights ~13.3M INCLUDING PREFERRED LEAN COST STRUCTURE IN PLACE $31M ELIMINATION OF IN DEBT YEARS OF PROJECTED CASH Over 4 MILESTONES EARNED SHARES OUTSTANDING ~8.2M BASIC
Slide 17: 2018 Business Objectives
2018 Business Objectives Further expand portfolio of fully-funded programs Out-license proprietary programs & phage display platform Acquire additional fully-funded programs Further strengthen balance sheet Eliminate legacy expense structure Enhance transaction capability to accelerate growth
Slide 18: XOMA: A De-risked way to Invest in Biotech
XOMA: A De-risked way to Invest in Biotech Model completely transformed to royalty aggregator with broad asset portfolio and capital resources to seize opportunities
Slide 19: ( ) JANUARY 2018
Corporate Presentation (Nasdaq: XOMA) JANUARY 2018